Interestingly, one smaller study with 59 primary breast cancer patients reported a negative correlation between ABCG2 mRNA expression and response rate and progression-free survival with anthracycline-based chemotherapy (Burger et al, 2003). This evidence concerns the gene ABCG2 and breast cancer.